Clinical characteristics of patients with sclGVHD after alloSCT
| Clinical characteristic . | Data . |
|---|---|
| Patients, N | 12 |
| Sex | |
| Female | 4 (33) |
| Male | 8 (67) |
| Age of recipient (mean ± SD), y | 49 ± 17 |
| Age of donor (mean ± SD), y | 42 ± 9 |
| Time between alloSCT and onset of cGVHD (mean ± SD), d | 250 ± 40 |
| Prior acute GVHD | 8 (75) |
| Clinically active disease | |
| Yes | 12 (100) |
| No | 0 (0) |
| Therapy | |
| CSA + Pred + Rux | 5 (42) |
| CSA + Pred + ECP | 4 (33) |
| CSA + Pred + MMF + ECP | 1 (8) |
| Steroid + CSA | 2 (17) |
| Clinical characteristic . | Data . |
|---|---|
| Patients, N | 12 |
| Sex | |
| Female | 4 (33) |
| Male | 8 (67) |
| Age of recipient (mean ± SD), y | 49 ± 17 |
| Age of donor (mean ± SD), y | 42 ± 9 |
| Time between alloSCT and onset of cGVHD (mean ± SD), d | 250 ± 40 |
| Prior acute GVHD | 8 (75) |
| Clinically active disease | |
| Yes | 12 (100) |
| No | 0 (0) |
| Therapy | |
| CSA + Pred + Rux | 5 (42) |
| CSA + Pred + ECP | 4 (33) |
| CSA + Pred + MMF + ECP | 1 (8) |
| Steroid + CSA | 2 (17) |
Unless otherwise noted, data are n (%).
CSA, cyclosporine A; ECP, extracorporeal photopheresis; MMF, mycophenolate mofetil; Pred, prednisolone; Rux, ruxolitinib.